Genetic Disorder Clinical Trial
Official title:
Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease
The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of the 3RP among patients living with VHL.
The 3RP has not been carried out with VHL patients. As such, the investigators are looking to see if an adapted program, tailored to the needs of patients with VHL, is feasible, acceptable, and helpful in improving coping among individuals living with VHL. This study is a two phase trial. Phase I is descriptive. It is comprised of conducting interviews with patients and caregivers to understand the challenges of living with VHL and patient's programatic needs. This information will be used to tailor the program for patients living with VHL. Phase II is a single-arm feasibility trial that will examine if the adapted program is feasible, acceptable, and helps promote stress management among VHL patients. To these means, we will test the adapted 3RP (3RP-VHL) in up to 40 patients living with VHL. Participants will complete surveys at baseline and post 3RP-VHL program completion. This record will reflect the trial component (Phase II) only, as feasibility and acceptability outcomes will be collected for this phase. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01734486 -
Growth Response in Girls With Turner Syndrome
|
Phase 4 | |
| Completed |
NCT01529944 -
Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658
|
Phase 3 | |
| Completed |
NCT01518036 -
Use of Somatropin in Turner Syndrome
|
Phase 3 | |
| Completed |
NCT00025870 -
Studies of Children With Metabolic and Other Genetic Disorders
|
||
| Completed |
NCT01563926 -
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
|
Phase 3 | |
| Active, not recruiting |
NCT01851447 -
Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy
|
||
| Completed |
NCT01435629 -
A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin
|
N/A | |
| Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
| Terminated |
NCT01135537 -
Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants
|
Phase 2 | |
| Completed |
NCT00705172 -
Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome
|
||
| Completed |
NCT01518062 -
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
|
Phase 4 | |
| Recruiting |
NCT02769949 -
Pediatric Patients With Metabolic or Other Genetic Disorders
|
||
| Terminated |
NCT00358657 -
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders
|
Phase 2 | |
| Completed |
NCT01604161 -
Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome
|
N/A | |
| Completed |
NCT01516229 -
Special Survey for Long Term Application
|
N/A | |
| Recruiting |
NCT03093220 -
Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis
|
N/A | |
| Enrolling by invitation |
NCT04681781 -
SLC13A5 Deficiency Natural History Study - Remote Only
|
||
| Completed |
NCT01529840 -
Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome
|
Phase 3 | |
| Completed |
NCT01710696 -
Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome
|
Phase 3 | |
| Completed |
NCT01401244 -
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
|
Phase 1 |